UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Enlarge Text
Click to increase the text size. Restore Text
Click to restore original text size. Reduce Text
Click to decrease the text size.


Decrease the text size \| Restore text size \| Increase the text size

SLC15A1

Synonyms: HPECT1, HPEPT1, PEPT1

Entrez Gene Link

Expression Data
Substrate Information
Inhibitor Information
Clinical Drug-drug Interactions

Expression Data

Expression data for other tissues could be found in http://pharmacogenetics.ucsf.edu/gtex/index.html

Asterisk indicates important transporters in the organ as identified in the organ diagram.

Organ	Source	Relative Expression
Brain	Nishimura	BLQ
Kidney*	Nishimura	`0.0292`
Liver	Nishimura	`0.0522`
Placenta	Nishimura	`0.00635`
Small Intestine*	Nishimura	`0.148`
Kidney*	Mean across all PMT Samples	`0.387`
Liver	Mean across all PMT Samples	`1.095`

Note that relative expression values should only be compared between entries of the same source.

Back to top

In Vitro Substrates

Substrate	Km (μM)	Cell System	Reference
5-aminolevulinic acid	394	PEPT1-expressing oocytes	Doring, 1998
5-aminolevulinic acid	1600	PEPT1-expressing oocytes	Anderson, 2010
Amoxicillin	ND	MDCK-PEPT1	Li, 2006
Bestatin	340	Caco-2	Saito, 1993
Cefadroxil	ND	HeLa-PEPT1	Knutter, 2009
Cephalexin	7.97	Caco-2	Watanabe, 2004
Enalapril	262	MDCK II-PEPT1	Liu, 2006
Glycylsarcosine	500	CHO-PEPT1	Han, 1999
Glycylsarcosine	310	Caco-2	Buyse, 2001
Glycylsarcosine	1100	Caco-2	Knutter, 2009
Oseltamivir	6540	Caco-2	Ogihara, 2009
Oseltamivir	8590	HeLa-PEPT1	Ogihara, 2009
Valacyclovir	5940	PEPT1-expressing oocytes	Balimane, 1998
Valacyclovir	1640	CHO-PEPT1	Guo, 1999

ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022

In Vitro Inhibitors

Inhibitor	Ki (μM)	Substrate used	Cell System	Reference
Fosinopril	35.5	Glycylsarcosine	Caco-2	Shu, 2001
Glycyl-proline	160	Glycylsarcosine	Caco-2	Brandsch, 1999
Irbesartan	230	Glycylsarcosine	Caco-2	Knutter, 2009
Losartan	24	Glycylsarcosine	Caco-2	Knutter, 2009
Losartan	52	Glycylsarcosine	HeLa-PEPT1	Knutter, 2009
Valacyclovir	910	Cefadroxil	CHO-PEPT1	Guo, 1999
Valacyclovir	4080	Glycylsarcosine	PEPT1-expressing oocytes	Balimane, 1998
Valacyclovir	1280	Glycylsarcosine	CHO-PEPT1	Guo, 1999
Valsartan	390	Glycylsarcosine	Caco-2	Knutter, 2009
Valsartan	560	Glycylsarcosine	HeLa-PEPT1	Knutter, 2009

Clinical Drug-Drug Interactions

No drug-drug interaction information.